Novo Nordisk has announced plans to acquire Akero Therapeutics for *$4.7 billion upfront, marking a major expansion into the *metabolic dysfunction-associated steatohepatitis (MASH) market. The deal underscores the Danish company’s ambition to dominate treatments in obesity-related liver disease, following FDA approval for adding MASH to the label of its GLP-1 drug semaglutide (Wegovy).
Key Points
- Acquisition Details
- Novo Nordisk will pay $54 per share in cash for Akero Therapeutics.
- An additional $6 per share (approx. $500 million) will be paid if Akero’s lead drug efruxifermin (EFX) wins U.S. FDA approval.
- Total potential deal value: $5.2 billion.
Strategic Rationale
- Efruxifermin is a fibroblast growth factor 21 (FGF21) analogue with the potential to achieve both first-in-class and best-in-class status. Its mechanism of action targets multiple metabolic pathways involved in glucose, lipid, and energy homeostasis.
- The acquisition (or partnership) strategically complements Novo Nordisk’s metabolic disease portfolio, reinforcing its leadership in diabetes and obesity while expanding its presence into liver-related complications such as nonalcoholic steatohepatitis (NASH) and related metabolic dysfunction-associated steatohepatitis (MASH).
- Efruxifermin’s differentiated biology aligns with Novo’s long-term objective of developing multi-organ metabolic solutions that go beyond glycemic control and weight management to address cardiometabolic and hepatic outcom
Clinical Profile of Efruxifermin
- Clinical Profile of Efruxifermin
- Only therapy to show significant fibrosis regression in MASH patients with compensated cirrhosis (F4).
- Undergoing three phase 3 trials covering both pre-cirrhotic (F2-F3) and cirrhotic (F4) stages.
Phase 2 results:
- Market Context
- MASH (formerly known as NASH) is a form of non-alcoholic fatty liver disease (NAFLD) associated with obesity and type 2 diabetes and affects millions globally.
- Novo’s Wegovy (semaglutide) recently became the second FDA-approved MASH drug after *Madrigal Pharma’s Rezdiffra (resmetirom), which already generated *$350 million** in H1 2025 sales.
- The acquisition positions Novo to potentially combine Wegovy and efruxifermin for synergistic liver and metabolic benefits.
Industry Comparisons
- Roche recently acquired 89bio and its FGF21 analogue pegozafermin for $2.4 billion upfront (up to $3.5 billion total).
- GSK is advancing its FGF21 candidate efimosfermin into phase 3 trials.
- The MASH therapeutic category is rapidly becoming a competitive growth frontier.
Leadership and Timeline
- This is the first major deal under Novo’s new CEO Mike Doustdar, appointed to strengthen the company’s metabolic disease leadership amid rising competition.
- The merger is expected to close by year-end 2025.
All Images Are AI Generated For Illustration Only. E&OE.
Sources
- Novo Nordisk press release (October 2025)
- Akero Therapeutics investor announcement
- Reuters and Bloomberg reports on the acquisition
- FierceBiotech and Endpoints News analyses on FGF21 pipeline and MASH market trends
- Clinical trial data from HARMONY and SYMMETRY phase 2 studies published by Akero Therapeutics
